NCT01399619View on ClinicalTrials.gov

Phase III Trial of BI 201335 (Faldaprevir) in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)-Human Immunodeficiency Virus (HIV) Coinfected Patients (STARTverso 4)

PHASE3CompletedINTERVENTIONAL
Enrollment

310

Participants

Timeline

Start Date

September 30, 2011

Primary Completion Date

September 30, 2013

Study Completion Date

June 30, 2014

Conditions
Hepatitis C, Chronic
Interventions
DRUG

PegIFN/RBV

PegIFN/RBV for 24 or 48w

DRUG

PegIFN/RBV

PegIFN/RBV for 24 or 48w

DRUG

BI201335

BI201335 for 12w

DRUG

BI201335 24W

BI201335 for 24w

DRUG

PegIFN/RBV

PegIFN/RBV for 24 or 48w

DRUG

Bi 201335

BI 201335 for 24 w

Trial Locations (71)

Unknown

1220.19.0045 Boehringer Ingelheim Investigational Site, Birmingham

1220.19.0007 Boehringer Ingelheim Investigational Site, Palm Springs

1220.19.0031 Boehringer Ingelheim Investigational Site, San Francisco

1220.19.0005 Boehringer Ingelheim Investigational Site, Washington D.C.

1220.19.0086 Boehringer Ingelheim Investigational Site, Fort Lauderdale

1220.19.0044 Boehringer Ingelheim Investigational Site, Orlando

1220.19.0004 Boehringer Ingelheim Investigational Site, Vero Beach

1220.19.0079 Boehringer Ingelheim Investigational Site, Lutherville

1220.19.0027 Boehringer Ingelheim Investigational Site, Framingham

1220.19.0008 Boehringer Ingelheim Investigational Site, Camden

1220.19.0009 Boehringer Ingelheim Investigational Site, Hillsborough

1220.19.0011 Boehringer Ingelheim Investigational Site, Albany

1220.19.0006 Boehringer Ingelheim Investigational Site, New York

1220.19.0014 Boehringer Ingelheim Investigational Site, New York

1220.19.0084 Boehringer Ingelheim Investigational Site, New York

1220.19.0021 Boehringer Ingelheim Investigational Site, Winston-Salem

1220.19.0013 Boehringer Ingelheim Investigational Site, Philadelphia

1220.19.0029 Boehringer Ingelheim Investigational Site, Austin

1220.19.0012 Boehringer Ingelheim Investigational Site, Dallas

1220.19.0060 Boehringer Ingelheim Investigational Site, Fort Worth

1220.19.0016 Boehringer Ingelheim Investigational Site, San Antonio

1220.19.0026 Boehringer Ingelheim Investigational Site, Richmond

1220.19.5508 Boehringer Ingelheim Investigational Site, Rio de Janeiro

1220.19.5502 Boehringer Ingelheim Investigational Site, Rio de Janeiro - RJ

1220.19.5506 Boehringer Ingelheim Investigational Site, Salvador

1220.19.5503 Boehringer Ingelheim Investigational Site, São Paulo

1220.19.5505 Boehringer Ingelheim Investigational Site, São Paulo

1220.19.5501 Boehringer Ingelheim Investigational Site, São Paulo - SP

1220.19.3306 Boehringer Ingelheim Investigational Site, Lyon

1220.19.3303 Boehringer Ingelheim Investigational Site, Marseille

1220.19.3304 Boehringer Ingelheim Investigational Site, Marseille

1220.19.3301 Boehringer Ingelheim Investigational Site, Paris

1220.19.3305 Boehringer Ingelheim Investigational Site, Paris

1220.19.3307 Boehringer Ingelheim Investigational Site, Paris

1220.19.4902 Boehringer Ingelheim Investigational Site, Berlin

1220.19.4921 Boehringer Ingelheim Investigational Site, Berlin

1220.19.4901 Boehringer Ingelheim Investigational Site, Bonn

1220.19.4924 Boehringer Ingelheim Investigational Site, Frankfurt am Main

1220.19.4919 Boehringer Ingelheim Investigational Site, Hamburg

1220.19.4920 Boehringer Ingelheim Investigational Site, Hamburg

1220.19.4905 Boehringer Ingelheim Investigational Site, München

1220.19.4922 Boehringer Ingelheim Investigational Site, München

1220.19.4923 Boehringer Ingelheim Investigational Site, Würzburg

1220.19.3901 Boehringer Ingelheim Investigational Site, Antella (fi)

1220.19.3902 Boehringer Ingelheim Investigational Site, Bari

1220.19.3906 Boehringer Ingelheim Investigational Site, Brescia

1220.19.3907 Boehringer Ingelheim Investigational Site, Milan

1220.19.3905 Boehringer Ingelheim Investigational Site, Pavia

1220.19.3903 Boehringer Ingelheim Investigational Site, Roma

1220.19.3904 Boehringer Ingelheim Investigational Site, Torino

1220.19.3404 Boehringer Ingelheim Investigational Site, Badalona

1220.19.3401 Boehringer Ingelheim Investigational Site, Barcelona

1220.19.3403 Boehringer Ingelheim Investigational Site, Barcelona

1220.19.3409 Boehringer Ingelheim Investigational Site, Barcelona

1220.19.3402 Boehringer Ingelheim Investigational Site, L'Hospitalet de Llobregat

1220.19.3405 Boehringer Ingelheim Investigational Site, Madrid

1220.19.3406 Boehringer Ingelheim Investigational Site, Madrid

1220.19.3407 Boehringer Ingelheim Investigational Site, Madrid

1220.19.3408 Boehringer Ingelheim Investigational Site, Seville

1220.19.4101 Boehringer Ingelheim Investigational Site, Basel

1220.19.4103 Boehringer Ingelheim Investigational Site, Bern

1220.19.4102 Boehringer Ingelheim Investigational Site, Lugano

1220.19.4104 Boehringer Ingelheim Investigational Site, Zurich

1220.19.4406 Boehringer Ingelheim Investigational Site, Brighton

1220.19.4407 Boehringer Ingelheim Investigational Site, Edinburgh

1220.19.4401 Boehringer Ingelheim Investigational Site, London

1220.19.4402 Boehringer Ingelheim Investigational Site, London

1220.19.4403 Boehringer Ingelheim Investigational Site, London

1220.19.4404 Boehringer Ingelheim Investigational Site, London

1220.19.4408 Boehringer Ingelheim Investigational Site, London

1220.19.4405 Boehringer Ingelheim Investigational Site, Manchester

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY